November 25 - Aurisco (605116) announced that its wholly-owned subsidiary, Yangzhou Aurisco Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate approved and issued by the National Medical Products Administration (NMPA) for Estradiol Tablets / Estradiol and Dydrogesterone Tablets Composite Packaging. The dosage form is tablets, with specifications as follows: each Estradiol Tablet contains 2mg of estradiol, and each Estradiol and Dydrogesterone Tablet contains 2mg of estradiol and 10mg of dydrogesterone.
As of October 31, 2025, the cumulative R&D investment in this drug project by the company amounted to approximately RMB 12.64 million.
This product is a dydrogesterone compound preparation originally developed by Abbott. It is used to treat perimenopausal syndrome caused by natural or surgical menopause. In 2015, the Estradiol Tablets / Estradiol and Dydrogesterone Tablets Composite Packaging, applied for by Abbott as an imported drug, was approved for marketing in China under the brand name "Femoston®".
Data from the NMPA website shows that, as of now, two companies in China have passed or are deemed to have passed the consistency evaluation for this drug: Abbott and Yangzhou Aurisco. According to market data, the hospital sales of "Femoston®" in 2024 reached RMB 564 million.
For the first three quarters of 2025, Aurisco reported revenue of RMB 1.237 billion and a net profit attributable to shareholders of RMB 354 million.

Reference：https://finance.eastmoney.com/a/202511253574218825.html